D.A. Davidson & Co. Galectin Therapeutics Inc Transaction History

D.A. Davidson & Co.

$11.2 Billion
Q2 2024

A detailed history of D.A. Davidson & Co. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 48,771 shares of GALT stock, worth $121,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,771

Previous 47,655 2.34%

Holding current value

$121,439

Previous $113,000 2.65%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$2.13 - $4.2 $2,377 - $4,687	1,116 Added 2.34%	48,771 $110,000
Q1 2024 May 13, 2024	BUY	$1.6 - $2.44 $8,000 - $12,200	5,000 Added 11.72%	47,655 $113,000
Q4 2023 Feb 09, 2024	BUY	$1.6 - $2.18 $7,728 - $10,529	4,830 Added 12.77%	42,655 $70,000
Q3 2023 Nov 08, 2023	BUY	$1.38 - $1.97 $6,899 - $9,850	5,000 Added 15.23%	37,825 $72,000
Q1 2023 Apr 25, 2023	BUY	$1.1 - $2.4 $16 - $36	15 Added 0.05%	32,825 $68,000
Q3 2022 Nov 07, 2022	SELL	$1.31 - $2.48 $16,407 - $31,062	-12,525 Reduced 27.63%	32,810 $53,000
Q2 2022 Jul 28, 2022	SELL	$1.19 - $1.74 $11,870 - $17,356	-9,975 Reduced 18.03%	45,335 $59,000
Q4 2021 Jan 31, 2022	SELL	$2.07 - $3.8 $4,140 - $7,600	-2,000 Reduced 3.49%	55,310 $114,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $10,360 - $16,600	-4,000 Reduced 6.52%	57,310 $222,000
Q2 2021 Aug 10, 2021	SELL	$2.07 - $5.1 $8,280 - $20,400	-4,000 Reduced 6.12%	61,310 $196,000
Q1 2021 May 07, 2021	SELL	$1.96 - $2.57 $1.38 Million - $1.8 Million	-702,011 Reduced 91.49%	65,310 $142,000
Q4 2020 Feb 10, 2021	SELL	$2.24 - $2.87 $193,524 - $247,953	-86,395 Reduced 10.12%	767,321 $1.72 Million
Q3 2020 Nov 02, 2020	BUY	$2.53 - $3.64 $6,615 - $9,518	2,615 Added 0.31%	853,716 $2.28 Million
Q2 2020 Aug 10, 2020	BUY	$1.66 - $3.15 $21,307 - $40,433	12,836 Added 1.53%	851,101 $2.6 Million
Q1 2020 May 05, 2020	SELL	$1.51 - $3.0 $4,051 - $8,049	-2,683 Reduced 0.32%	838,265 $1.64 Million
Q4 2019 Feb 14, 2020	BUY	$2.79 - $4.32 $58,004 - $89,812	20,790 Added 2.53%	840,948 $2.41 Million
Q3 2019 Nov 05, 2019	BUY	$3.0 - $4.05 $87,852 - $118,600	29,284 Added 3.7%	820,158 $3.01 Million
Q2 2019 Aug 13, 2019	BUY	$3.61 - $5.0 $131,833 - $182,595	36,519 Added 4.84%	790,874 $3.28 Million
Q1 2019 May 13, 2019	BUY	$3.86 - $6.02 $136,767 - $213,300	35,432 Added 4.93%	754,355 $3.86 Million
Q4 2018 Jan 29, 2019	BUY	$3.43 - $5.74 $101,682 - $170,162	29,645 Added 4.3%	718,923 $2.47 Million
Q3 2018 Nov 13, 2018	BUY	$3.68 - $6.93 $120,523 - $226,964	32,751 Added 4.99%	689,278 $4.14 Million
Q2 2018 Aug 02, 2018	SELL	$3.16 - $9.16 $236,282 - $684,920	-74,773 Reduced 10.22%	656,527 $4.18 Million
Q1 2018 May 04, 2018	BUY	$3.78 - $5.97 $163,095 - $257,587	43,147 Added 6.27%	731,300 $3.47 Million
Q4 2017 Feb 08, 2018	SELL	$1.54 - $3.34 $4,322 - $9,375	-2,807 Reduced 0.41%	688,153 $2.3 Million
Q3 2017 Nov 08, 2017	SELL	$1.67 - $2.3 $79,391 - $109,341	-47,540 Reduced 6.44%	690,960 $1.48 Million
Q2 2017 Aug 11, 2017	BUY	N/A	738,500	738,500 $0

Others Institutions Holding GALT

# of Institutions

Shares Held

9.36M

Call Options Held

982K

Put Options Held

2.7K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $148M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account